Previous 10 | Next 10 |
London-based Okyo Pharma ( NASDAQ: OKYO ) it received customs clearance in the U.S. for its GMP packaged OK-101 drug, shipped from Europe, to be used in an upcoming phase 2 trial in patients with dry eye disease (DED). Okyo expects the first-patient-first visit in Q1 2023 an...
LONDON and NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today anno...
(NewsDirect) By David Willey, Benzinga An eye condition that has been described as a common disease currently affects as many as 49 million Americans . Dry Eye Disease (DED) afflicts over 15% of Americans over 50 and disproportionately affects women and DED patients are not well s...
--News Direct-- By David Willey, Benzinga An eye condition that has been described as a common disease currently affects as many as 49 million Americans . Dry Eye Disease (DED) afflicts over 15% of Americans over 50 and disproportionately affects women and DED patients are not wel...
LONDON and NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announces the...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Alex Kravtsov / Shutterstock.com Alibaba (NYSE: BABA ) stock is a hot topic on Tuesday as investors react to news of Ant Group teaming up with China’s NBA league . With this news, Ant Group, a fi...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock OKYO Pharma (NASDAQ: OKYO ) stock is falling on Tuesday as the company prepares for a presentation this week . OKYO Pharma is attending the 2nd Annual GPCRs-Targeted Drug Discovery Summi...
LONDON and NEW YORK, Feb. 21, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) (“OKYO”, “OKYO Pharma” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to addre...
LONDON and NEW YORK, Dec. 30, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announces its...
The U.S. Food and Drug Administration (FDA) cleared Okyo Pharma's ( NASDAQ: OKYO ) investigational new drug (IND) to start a phase 2 trial of OK-101 for treating dry eye disease (DED). The London-based company said that the FDA previously agreed with its plans for designating...
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...